RESPONSE TO T-DM1 IN HER2-POSITIVE BREAST CANCER BRAIN METASTASES (BM)

被引：0
|
作者：
Berghoff, A. S. [1 ]
Bartsch, R. [1 ]
Bergen, E. [1 ]
Rudas, M. [2 ]
Gnant, M. [3 ]
Dieckmann, K. [4 ]
Pinker, K. [5 ]
Zielinski, C. C. [1 ]
Steger, G. G. [1 ]
Preusser, M. [1 ]
机构：
[1] Med Univ Vienna, Dept Med 1, Clin Div Oncol, Vienna, Austria
[2] Med Univ Vienna, Dept Pathol, Vienna, Austria
[3] Med Univ Vienna, Dept Surg, Vienna, Austria
[4] Med Univ Vienna, Dept Radiotherapy, Vienna, Austria
[5] Med Univ Vienna, Dept Radiol, Vienna, Austria
来源：
NEURO-ONCOLOGY | 2014年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P08.01
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Dual endothelin receptor inhibition enhances T-DM1 efficacy in brain metastases from HER2-positive breast cancer
    Vasileios Askoxylakis
    Gino B. Ferraro
    Mark Badeaux
    David P. Kodack
    Isabelle Kirst
    Ram C. Shankaraiah
    Christina S. F. Wong
    Dan G. Duda
    Dai Fukumura
    Rakesh K. Jain
    npj Breast Cancer, 5
  • [22] Preclinical evaluation of neratinib plus T-DM1 in orthotopic PDX models of HER2-positive breast cancer brain metastases
    Ni, Jing
    Wang, Yanzhi
    Diala, Irmina
    Kabraji, Sheheryar
    Freedman, Rachel
    Lin, Nancy
    Zhao, Jean
    CANCER RESEARCH, 2019, 79 (13)
  • [23] Dual endothelin receptor inhibition enhances T-DM1 efficacy in brain metastases from HER2-positive breast cancer
    Askoxylakis, Vasileios
    Ferraro, Gino B.
    Badeaux, Mark
    Kodack, David P.
    Kirst, Isabelle
    Shankaraiah, Ram C.
    Wong, Christina S. F.
    Duda, Dan G.
    Fukumura, Dai
    Jain, Rakesh K.
    NPJ BREAST CANCER, 2019, 5 (1)
  • [24] Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancer
    Ma, Bo
    Ma, Qianqian
    Wang, Hongqiang
    Zhang, Guolei
    Zhang, Huiying
    Wang, Xiaohong
    ONCOTARGETS AND THERAPY, 2016, 9 : 959 - 976
  • [25] Pertuzumab and T-DM1: New perspectives in the treatment of HER2-positive breast cancer
    Guiu, S.
    Fumoleau, P.
    ONCOLOGIE, 2015, 17 (5-6) : 263 - 270
  • [26] Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
    Hunter, Francis W.
    Barker, Hilary R.
    Lipert, Barbara
    Rothe, Francoise
    Gebhart, Geraldine
    Piccart-Gebhart, Martine J.
    Sotiriou, Christos
    Jamieson, Stephen M. F.
    BRITISH JOURNAL OF CANCER, 2020, 122 (05) : 603 - 612
  • [27] Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
    Francis W. Hunter
    Hilary R. Barker
    Barbara Lipert
    Françoise Rothé
    Géraldine Gebhart
    Martine J. Piccart-Gebhart
    Christos Sotiriou
    Stephen M. F. Jamieson
    British Journal of Cancer, 2020, 122 : 603 - 612
  • [28] Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1
    C. L. Gorter de Vries
    S. C. Linn
    D. Brandsma
    Journal of Neuro-Oncology, 2016, 127 : 401 - 403
  • [29] Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1
    de Vries, C. L. Gorter
    Linn, S. C.
    Brandsma, D.
    JOURNAL OF NEURO-ONCOLOGY, 2016, 127 (02) : 401 - 403
  • [30] Ado-trastuzumab emtansine (T-DM1) is effective against established HER2-positive breast cancer brain metastases in mice
    Askoxylakis, V.
    Ferraro, G.
    Kodack, D.
    Badeaux, M.
    Jain, R.
    CANCER RESEARCH, 2016, 76
12345